Atlas Trials

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Clinical trial NCT06007937 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06007937
Sponsor
Memorial Sloan Kettering Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung CancerMetastaticRecurrent
Start date
2023-08-17
Primary completion
2028-08-17
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.